Cellular Origins acquires Actia Platform IP to enhance automated cell therapy manufacturing

FHS
July 2, 2024
10:06 am

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge whilst CEO of SOTIO Biotech US. The ACTIA Platform complements Cellular Origins’ existing approach and will accelerate and expand R&D efforts to further develop the Company’s robotic solution for automated cell therapy manufacturing, Constellation™.

Making Adjustments to Home Environment May Ease Dry Eye Disease Symptoms

A recent study examined how indoor environmental conditions can affect dry eye disease symptoms and assessed whether home interventions can improve ocular health. The results

November 21, 2023

New study shows the effectiveness of alcohol calorie labeling

Just over half of heavier drinkers in England say they would make changes to their drinking if calorie labels for alcohol were introduced, according to

September 19, 2024

European research project seeks faster depression treatment solutions

Depression can affect anyone. It is common, and in many cases severe. These days, there are good treatments available, typically involving a combination of psychotherapy

January 11, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.